The Burrill Report
View as an RSS Feed
View The Burrill Report's Articles BY TICKER:
ABT, AFFX, AFFY, AMGN, AMRS, AZN, BIIB, BSX, CELG, CEPH, CI, CLVS, CRL, CRXL, CTIC, CYPB, DCGN, DD, DNDN, ELN, ENDP, EXEL, FRX, GE, GERN, GILD, GLPYY, GNMSF, GNOM, GSK, HPTX, HZNP, ILMN, IYH, JNJ, LIFE, LLY, MACK, MDVN, MNKD, MRK, MYGN, NVS, OREX, PFE, RHHBY, RIGL, RPTP, SHPG, SI, SNY, SZYM, TEVA, VRTX, VVUS, WLP, WX, WYE, XOMA, XPH
- Eli Lilly Plans Innovation Strategy to Counter Generics Threat
- BlueFire, Archer Daniels to Benefit from Federal Biorefinery Millions
- Financing Drug Discovery: Recent Deals
- Novartis Partners with U.S. Government for Faster Flu Vaccine Manufacturing
- Merck Triumphs in Defense of Osteoporosis Drug...for Now
- Bristol-Myers Squibb Sees Perfect Timing to Divest Huge Mead Johnson Nutrition Stake
- Vitamin Beats Statin: Is Merck's Zetia in Trouble?
- Sanofi-Aventis to Establish Venture Capital Fund, Looking for 'Right Brain Activity'
- Big Pharma Willing to Pay for Biotech Innovation
- Biotech Blooms at Eli Lilly
- China Is Growth Market for Novartis
- Lilly Hopes New San Diego Facility Will Be 'a Biotechnology Powerhouse'
Healthcare Waste Spending Pegged at $700 Billion - Thomson Reuters Report
on Nov. 1, 2009 • Comment!
- Biotech Tribulations Roundup: Failed Trials, Missed Targets, Business Mishaps
- This Week in Biotech: More Treats than Tricks
- Venture Capital Flows to Biotech as Public Financing Takes a Breather
- GE's New Fund Hopes to Help 'Shape the Future of Healthcare'
- Little Difference Between Roche's Avastin and Lucentis for Macular Degeneration
- Biotech Companies Turn to Capital Markets
- Capital Markets Open Up to Biotechs
- Financing Activity for Biotech Deals Heats Up
- Three Life Science Companies Line Up for IPOs
- Biotech Busy with Bevy of Small Deals
- Summer Ends with Biotech Buying Spree
- Several Promising Deals for Biotech
- Biotech Dealmaking Takes a Summer Breather
- A Depressed Housing Market: Foreclosures Spark Mental Health Crisis
- Two Life Science Companies Manage to Pry Open IPO Window
- Biotech Discounts Galore
- July Was a Good Month for Biotech
- VC Financings Boost Interest in Biotech
The Future of Biotech: Evolve or Die
on Jul. 24, 2009 • Comment!